JP2017535569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535569A5 JP2017535569A5 JP2017527621A JP2017527621A JP2017535569A5 JP 2017535569 A5 JP2017535569 A5 JP 2017535569A5 JP 2017527621 A JP2017527621 A JP 2017527621A JP 2017527621 A JP2017527621 A JP 2017527621A JP 2017535569 A5 JP2017535569 A5 JP 2017535569A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- acceptable salt
- riluzole
- ibudilast
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 23
- ZJVFLBOZORBYFE-UHFFFAOYSA-N Ibudilast Chemical compound C1=CC=CC2=C(C(=O)C(C)C)C(C(C)C)=NN21 ZJVFLBOZORBYFE-UHFFFAOYSA-N 0.000 claims 14
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 14
- 229960002491 ibudilast Drugs 0.000 claims 14
- 229960004181 riluzole Drugs 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 11
- 208000015122 neurodegenerative disease Diseases 0.000 claims 10
- 230000004770 neurodegeneration Effects 0.000 claims 9
- 230000000750 progressive effect Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 5
- 230000007823 neuropathy Effects 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 206010033799 Paralysis Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 239000002775 capsule Substances 0.000 claims 3
- 208000010118 dystonia Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 239000008297 liquid dosage form Substances 0.000 claims 3
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 206010017065 Foster-Kennedy Syndrome Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- 206010036105 Polyneuropathy Diseases 0.000 claims 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 208000005392 Spasm Diseases 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 208000018839 Wilson disease Diseases 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 2
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- 208000027776 Extrapyramidal disease Diseases 0.000 claims 1
- 206010016212 Familial tremor Diseases 0.000 claims 1
- 208000025329 Fazio-Londe disease Diseases 0.000 claims 1
- 208000001799 Hereditary Optic Atrophies Diseases 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010023201 Joint contracture Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000010428 Muscle Weakness Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 claims 1
- 108010012715 Superoxide dismutase Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010044074 Torticollis Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 208000010399 Wasting Syndrome Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 208000018300 basal ganglia disease Diseases 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000006517 essential tremor Diseases 0.000 claims 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000002161 motor neuron Anatomy 0.000 claims 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 230000001338 necrotic effect Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 208000021090 palsy Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 238000005096 rolling process Methods 0.000 claims 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 230000001953 sensory effect Effects 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000003755 striatonigral degeneration Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084879P | 2014-11-26 | 2014-11-26 | |
| US62/084,879 | 2014-11-26 | ||
| PCT/US2015/062456 WO2016085998A1 (en) | 2014-11-26 | 2015-11-24 | Combination of ibudilast and riluzole and methods of using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535569A JP2017535569A (ja) | 2017-11-30 |
| JP2017535569A5 true JP2017535569A5 (enExample) | 2019-01-10 |
| JP6827924B2 JP6827924B2 (ja) | 2021-02-10 |
Family
ID=56074979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527621A Active JP6827924B2 (ja) | 2014-11-26 | 2015-11-24 | イブジラスト及びリルゾールの組み合わせを含む医薬および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US10258611B2 (enExample) |
| EP (1) | EP3223815B1 (enExample) |
| JP (1) | JP6827924B2 (enExample) |
| KR (1) | KR102462638B1 (enExample) |
| CN (1) | CN107205986A (enExample) |
| BR (1) | BR112017010700A2 (enExample) |
| CA (1) | CA2967826C (enExample) |
| ES (1) | ES2891306T3 (enExample) |
| WO (1) | WO2016085998A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021530543A (ja) * | 2018-07-22 | 2021-11-11 | バイオヘイブン・セラピューティクス・リミテッドBiohaven Therapeutics Ltd. | アルツハイマー病を処置するためのリルゾールプロドラッグの使用 |
| CN112584831A (zh) * | 2018-08-16 | 2021-03-30 | 拜奥海芬治疗学有限公司 | 利鲁唑口腔崩解片用于治疗疾病的用途 |
| ES2970996T3 (es) | 2018-10-19 | 2024-06-03 | Medicinova Inc | Tratamiento de la lesión macular asociada a la esclerosis múltiple con ibudilast |
| EP4031135A4 (en) | 2019-09-20 | 2023-10-18 | Icahn School of Medicine at Mount Sinai | CONTROLLED RELEASE FORMULATIONS OF RILUZOLE AND USES THEREOF |
| EP4240308A4 (en) * | 2020-10-05 | 2024-10-30 | Icahn School of Medicine at Mount Sinai | Riluzole for the treatment of alzheimer's disease |
| JP2024528731A (ja) | 2021-07-26 | 2024-07-30 | メディシノバ・インコーポレイテッド | 眼癌転移を予防するためのイブジラスト |
| US12042485B2 (en) | 2021-10-07 | 2024-07-23 | Medicinova, Inc. | Methods of minimizing cancer metastasis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2585246A1 (fr) | 1985-07-26 | 1987-01-30 | Cortial | Procede d'obtention de formes pharmaceutiques solides a liberation prolongee |
| US4788055A (en) | 1985-12-09 | 1988-11-29 | Ciba-Geigy Corporation | Resinate sustained release dextromethorphan composition |
| GB8613689D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB8613688D0 (en) | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| US4816264A (en) | 1986-06-06 | 1989-03-28 | Warner-Lambert Company | Sustained release formulations |
| US4996047A (en) | 1988-11-02 | 1991-02-26 | Richardson-Vicks, Inc. | Sustained release drug-resin complexes |
| CA2002492A1 (en) | 1988-11-11 | 1990-05-11 | Sandra T. A. Malkowska | Pharmaceutical ion exchange resin composition |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| CA2375874A1 (en) | 1999-06-04 | 2000-12-14 | Chris Polman | Use of riluzole for the treatment of multiple sclerosis |
| WO2004105756A2 (en) | 2003-05-29 | 2004-12-09 | Novartis Ag | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| WO2006063048A2 (en) | 2004-12-06 | 2006-06-15 | Avigen, Inc. | Ibudilast for treating neuropathic pain and associated syndromes |
| CA2693697C (en) * | 2007-07-11 | 2017-07-25 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
-
2015
- 2015-11-24 US US15/527,280 patent/US10258611B2/en active Active
- 2015-11-24 ES ES15863670T patent/ES2891306T3/es active Active
- 2015-11-24 KR KR1020177015476A patent/KR102462638B1/ko active Active
- 2015-11-24 CN CN201580064290.9A patent/CN107205986A/zh active Pending
- 2015-11-24 CA CA2967826A patent/CA2967826C/en active Active
- 2015-11-24 BR BR112017010700A patent/BR112017010700A2/pt not_active Application Discontinuation
- 2015-11-24 EP EP15863670.4A patent/EP3223815B1/en active Active
- 2015-11-24 JP JP2017527621A patent/JP6827924B2/ja active Active
- 2015-11-24 WO PCT/US2015/062456 patent/WO2016085998A1/en not_active Ceased
-
2019
- 2019-02-28 US US16/289,636 patent/US20200030301A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,911 patent/US11278531B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7627514B2 (ja) | Ｒ－ケタミンおよびその塩の医薬品としての応用 | |
| Gadhave et al. | Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance | |
| JP2021075556A5 (enExample) | ||
| Brodie et al. | Zonisamide: its pharmacology, efficacy and safety in clinical trials | |
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| JP2005501801A5 (enExample) | ||
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| WO2016190780A1 (en) | Extracellular dna as a therapeutic target in neurodegeneration | |
| CN110300581B (zh) | 具有奇数碳的脂类化合物及其作为医药组合物或者营养补充剂的用途 | |
| Salas-Vargas et al. | Spinocerebellar ataxia type 7: a neurodegenerative disorder with peripheral neuropathy | |
| Chaves et al. | Functional neuroimaging of minocycline's effect in a patient with schizophrenia | |
| JP2017513845A5 (enExample) | ||
| Specchio et al. | Efficacy of levetiracetam in the treatment of drug-resistant Rett syndrome | |
| Gilhuis et al. | Demyelinating polyneuropathy in Leber hereditary optic neuropathy | |
| Kelemen et al. | Lecithin is not effective in amyotrophic lateral sclerosis | |
| BRPI0517460A (pt) | análogos canabinóides eficazes de administração oral | |
| Smith et al. | Inhibitory motor status: two new cases and a review of inhibitory motor seizures | |
| Jain et al. | REVISITING SUSHRUTA SAMHITA AND INVESTIGATING THE POTENTIAL LINK BETWEEN ITS TREATMENT MODALITIES BY PREDICTING STUDY USING BIOINFORMATICS | |
| Hajilou | Review of different applications of sildenafil with the focus on its role in Alzheimer's disease | |
| RU2013139704A (ru) | Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера | |
| Dontiboina et al. | Mechanism of Neurodegeneration in Other Neurodegenerative Diseases | |
| MXPA05000451A (es) | Composicion medicinal para neuropatia inducida por farmaco. | |
| Chinthapalli | Pharmacological treatment | |
| Yadava et al. | Pharmacological, Non-Pharmacological, and Emerging Therapies for Other Neurodegenerative Diseases |